IBD-RESPONSE is a UK-wide multi-centre observational cohort study that will develop a predictive algorithm for response or failure to respond to biologic, janus kinase inhibitor (JAKi) and sphingosine-1-phosphate receptor (S1PR) modulator therapies in Crohn's disease and ulcerative colitis.
Launched in 2022 our precision medicine research will follow 1,325 patients for the first year after commencing one of these therapies.
We will utilise multiple cutting edge technologies to study the gut microbiome, the human genome and immune system integrated with clinical outcome data utilising machine learning techniques.
Watch our summary video below
Hear more about the study from our Chief Investigator
